National Pharmaceutical Pricing Authority has revised the prices of 100 domestically manufactured medicine packs in its monthly price review meeting held on June 28. The authority did not consider the price revision of any imported medicine.
The drugs whose prices were revised include the first price fixation of certain combination medicines such as commonly prescribed combiflam, a combination of Ibuprofen and paracetamol. A 15-tablet strip of combiflam would now carry a maximum retail price, inclusive of all taxes, of Rs 12.37. Other medicine packs whose prices have come under review include human insulin, ranitidine and salbutamol. In a July 1 notification, the apex medicine price regulator said it had also reviewed the prices of three bulk drugs (key raw materials) after a gap of three years. The prices reviewed are those of bulk drugs cefadroxyl monohydrate (from Rs 2758/kg to Rs 2951/kg), metronidazole (from Rs 526/kg to Rs 514/kg) and metronidazole benzoate (from Rs 447/kg to Rs 450/kg).
Drug companies marketing these products would have to revise their prices within 15 days from the date of notification. The National Pharmaceutical Pricing Authority would consider imported medicines in its next meeting which is likely this month.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
